title: Pharmacokinetics of prothionamide in patients with multidrug-resistant tuberculosis.
abstract: METHODS
  National Masan Tuberculosis Hospital, Masan, South Korea.
  
  
  OBJECTIVE
  To evaluate the pharmacokinetics of prothionamide (PTH) in South Korean patients with multidrug-resistant tuberculosis (MDR-TB) and to investigate whether differences in body mass index (BMI) could explain observed differences in PTH disposition.
  
  
  METHODS
  Seventeen patients participated in the study; all had MDR-TB and had received combination anti-tuberculosis treatment, including PTH, cycloserine, ofloxacin, para-aminosalicylic acid and streptomycin or kanamycin, for at least 2 weeks. The patients were divided into two groups based on BMI: Group A (18.5 < or = BMI<23), and Group B (BMI<18.5). Serum samples were collected over 24 h, and the plasma PTH concentration was determined by a validated high-performance liquid chromatography assay.
  
  
  RESULTS
  After steady-state administration of PTH, the mean area under the plasma concentration-time curve from time 0 to 12 h (AUC(0-12h)) was 11.0 +/- 3.7 microg h/ml. The mean T(max) and t(1/2) were respectively 3.6 h and 2.7 h. No significant difference in PTH disposition was observed between groups A and B, except for ke and t(1/2).
  
  
  CONCLUSIONS
  In the pharmacokinetic parameter estimates for PTH in MDR-TB patients during routine treatment, the pharmacokinetics of PTH did not appear to correlate with extent of emaciation in MDR-TB patients.
authors.affiliation: Clinical Trial Centre, Kyungpook National University Hospital, Daegu, Korea; Department of Molecular Medicine, Kyungpook National University School of Medicine, Daegu, Korea.
authors.forename: H W
authors.initials: HW
authors.lastname: Lee
authors.forename: D W
authors.initials: DW
authors.lastname: Kim
authors.forename: J H
authors.initials: JH
authors.lastname: Park
authors.forename: S-D
authors.initials: SD
authors.lastname: Kim
authors.forename: M-S
authors.initials: MS
authors.lastname: Lim
authors.forename: P B
authors.initials: PB
authors.lastname: Phapale
authors.forename: E-H
authors.initials: EH
authors.lastname: Kim
authors.forename: S K
authors.initials: SK
authors.lastname: Park
authors.forename: Y-R
authors.initials: YR
authors.lastname: Yoon
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D019540:Area Under Curve; D015992:Body Mass Index; D002851:Chromatography, High Pressure Liquid; D004359:Drug Therapy, Combination; D004614:Emaciation / Q000378:metabolism / Q000382:microbiology; D005260:Female; D006207:Half-Life; D006801:Humans; D008297:Male; D008875:Middle Aged; D011515:Prothionamide / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D056910:Republic of Korea; D016896:Treatment Outcome; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy* / Q000378:metabolism / Q000382:microbiology; D055815:Young Adult
chemical_list: D000995:Antitubercular Agents; D011515:Prothionamide